Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events "DECLARE-TIMI58"

Active, not recruiting

Phase 3 Results N/A

Eligibility Criteria

Inclusion Criteria

- Provision of informed consent prior to any study specific procedures
- Female or male aged ≥40 years
- Diagnosed with Type 2 Diabetes
- High Risk for Cardiovascular events

Exclusion Criteria

- Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
- Chronic cystitis and/or recurrent urinary tract infections
- Pregnant or breast-feeding patients